302 related articles for article (PubMed ID: 16677395)
21. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.
van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Osterborg A; Jacobson SH; Klareskog L
Scand J Rheumatol; 2004; 33(6):423-7. PubMed ID: 15794203
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
[TBL] [Abstract][Full Text] [Related]
23. Rituximab treatment in lupus nephritis--where do we stand?
Gunnarsson I; Jonsdottir T
Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
[TBL] [Abstract][Full Text] [Related]
24. Exploring new territory: the move towards individualised treatment.
Haubitz M
Lupus; 2007; 16(3):227-31. PubMed ID: 17432112
[TBL] [Abstract][Full Text] [Related]
25. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
26. Rituximab and lupus--a promising pair?
Ekö SL; van Vollenhoven RF
Curr Rheumatol Rep; 2014; 16(9):444. PubMed ID: 25074032
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
28. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
29. [Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab].
Tsanyan ME; Torgashina AV; Aleksandrova EN; Soloviev SK; Nasonov EL
Ter Arkh; 2013; 85(5):53-9. PubMed ID: 23819340
[TBL] [Abstract][Full Text] [Related]
30. A Case of NCAM1-Positive Lupus Nephritis with NCAM1 Antibody Titers Responsive to Rituximab.
Wang Y; Chen R; Han M; Liu S; Xie Q; Hao C
Nephron; 2024; 148(5):312-318. PubMed ID: 37778328
[TBL] [Abstract][Full Text] [Related]
31. Remission of refractory lupus nephritis with a protocol including rituximab.
Fra GP; Avanzi GC; Bartoli E
Lupus; 2003; 12(10):783-7. PubMed ID: 14596429
[TBL] [Abstract][Full Text] [Related]
32. Risk of clinical deterioration in patients with lupus nephritis receiving rituximab.
Manou-Stathopoulou S; Robson MG
Lupus; 2016 Oct; 25(12):1299-306. PubMed ID: 27084027
[TBL] [Abstract][Full Text] [Related]
33. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
34. B-cell depletion in the treatment of lupus nephritis.
Gregersen JW; Jayne DR
Nat Rev Nephrol; 2012 Sep; 8(9):505-14. PubMed ID: 22801948
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.
Tanaka Y; Takeuchi T; Miyasaka N; Sumida T; Mimori T; Koike T; Endo K; Mashino N; Yamamoto K
Mod Rheumatol; 2016; 26(1):80-6. PubMed ID: 26054418
[TBL] [Abstract][Full Text] [Related]
36. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
Pepper R; Griffith M; Kirwan C; Levy J; Taube D; Pusey C; Lightstone L; Cairns T
Nephrol Dial Transplant; 2009 Dec; 24(12):3717-23. PubMed ID: 19617257
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in the treatment of refractory lupus nephritis with vasculitis.
Kadikoy H; Haque W; Ahmed S; Abdellatif A
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):334-7. PubMed ID: 22382230
[TBL] [Abstract][Full Text] [Related]
38. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.
Gomez Mendez LM; Cascino MD; Garg J; Katsumoto TR; Brakeman P; Dall'Era M; Looney RJ; Rovin B; Dragone L; Brunetta P
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1502-1509. PubMed ID: 30089664
[TBL] [Abstract][Full Text] [Related]
39. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Sfikakis PP; Boletis JN; Tsokos GC
Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
[TBL] [Abstract][Full Text] [Related]
40. Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: a case report.
Bienaimé F; Quartier P; Dragon-Durey MA; Frémeaux-Bacchi V; Bader-Meunier B; Patey N; Salomon R; Noël LH
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1346-50. PubMed ID: 20191570
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
